David T. Giddings

David T. Giddings

Chief Executive Officer at Allotrope Pharmaceuticals

Health Technology
Consumer Services
Distribution Services

Profile

David T.
Giddings
is currently the Chief Executive Officer at Allotrope Pharmaceuticals.
Previously, he served as Chairman, President & Chief Executive Officer at Diametrics Medical, Inc. from 1996 to 2002.
He was also the Director at LipoScience, Inc. from 2004 to 2011, and held director positions at Gentra Systems, Inc., HeartSine Technologies LLC, Axela, Inc., Accpac International, Inc., and Boehringer Mannheim Canada Ltd.
He was the President & Chief Operating Officer at Digilab, Inc. and the Principal at Eastman Kodak Co. He earned his undergraduate degree from Middlebury College and his MBA from Rider University.

David T. Giddings active positions

CompaniesPositionStart
Allotrope Pharmaceuticals Chief Executive Officer -
All active positions of David T. Giddings

Former positions of David T. Giddings

CompaniesPositionEnd
LIPOSCIENCE INC Director/Board Member 2011-03-07
Chairman 2001-12-31
Boehringer Mannheim Corp. (California) President 2001-12-31
Director/Board Member -
Director/Board Member -
See the detail of David T. Giddings's experience

Training of David T. Giddings

Middlebury College Undergraduate Degree
Rider University Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David T. Giddings's experience

Connections

15

1st degree connections

13

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
EASTMAN KODAK COMPANY

Producer Manufacturing

Private companies10

Distribution Services

Health Technology

Process Industries

Health Technology

Health Technology

Health Technology

Accpac International, Inc.

Boehringer Mannheim Canada Ltd.

Boehringer Mannheim Corp. (California)

Allotrope Pharmaceuticals

See company connections
  1. Stock Market
  2. Insiders
  3. David T. Giddings
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW